← Back to Screener
Corcept Therapeutics Inc. (CORT)
Price$46.34
Favorite Metrics
Price vs S&P 500 (26W)-46.34%
Price vs S&P 500 (4W)23.76%
Market Capitalization$4.90B
P/E Ratio (Annual)49.18x
All Metrics
P/CF (Annual)34.51x
Book Value / Share (Quarterly)$6.11
P/TBV (Annual)5.18x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)23.74%
Cash Flow / Share (Quarterly)$1.34
Price vs S&P 500 (YTD)28.51%
Gross Margin (TTM)98.30%
Net Profit Margin (TTM)13.09%
EPS (TTM)$0.83
10-Day Avg Trading Volume1.10M
EPS Excl Extra (TTM)$0.83
Revenue Growth (5Y)16.56%
EPS (Annual)$0.83
ROI (Annual)15.38%
Gross Margin (Annual)98.30%
Net Profit Margin (5Y Avg)22.40%
Cash / Share (Quarterly)$3.56
P/E Basic Excl Extra (TTM)49.18x
Revenue Growth QoQ (YoY)11.12%
EPS Growth (5Y)-0.54%
P/E Normalized (Annual)49.18x
ROA (Last FY)11.91%
Revenue Growth TTM (YoY)12.79%
EBITD / Share (TTM)$0.38
ROE (5Y Avg)21.45%
Operating Margin (TTM)5.88%
Cash Flow / Share (Annual)$1.34
P/B Ratio7.57x
P/B Ratio (Quarterly)11.40x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)6.28x
Net Interest Coverage (TTM)106.60x
ROA (TTM)12.05%
EPS Growth QoQ (YoY)-21.52%
EV / EBITDA (TTM)104.04x
EPS Incl Extra (Annual)$0.83
Current Ratio (Annual)2.92x
Quick Ratio (Quarterly)2.71x
3-Month Avg Trading Volume2.08M
52-Week Price Return-28.54%
EV / Free Cash Flow (Annual)33.71x
P/E Incl Extra (TTM)49.18x
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$4.48
P/S Ratio (Annual)6.44x
Asset Turnover (Annual)0.91x
52-Week High$91.00
Operating Margin (5Y Avg)22.09%
EPS Excl Extra (Annual)$0.83
CapEx CAGR (5Y)-29.36%
Tangible BV CAGR (5Y)21.32%
26-Week Price Return-37.59%
Quick Ratio (Annual)2.71x
13-Week Price Return24.62%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)2.92x
Enterprise Value$4,780.156
Revenue / Share Growth (5Y)17.37%
Asset Turnover (TTM)0.92x
Book Value / Share Growth (5Y)6.39%
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)1.03x
Pretax Margin (Annual)8.73%
Cash / Share (Annual)$3.56
3-Month Return Std Dev72.59%
Gross Margin (5Y Avg)98.51%
Net Income / Employee (TTM)$0
EBITDA CAGR (5Y)-18.62%
EBITDA Interim CAGR (5Y)-31.03%
ROE (Last FY)15.38%
Net Interest Coverage (Annual)19.77x
EPS Basic Excl Extra (Annual)$0.83
P/FCF (TTM)34.56x
Receivables Turnover (TTM)13.39x
EV / Free Cash Flow (TTM)33.71x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$0.83
Receivables Turnover (Annual)13.39x
ROI (TTM)15.34%
P/S Ratio (TTM)6.44x
Pretax Margin (5Y Avg)24.31%
Revenue / Share (Annual)$6.35
Tangible BV / Share (Annual)$3.83
Forward P/E123.27x
Free OCF CAGR (5Y)-1.23%
Price vs S&P 500 (52W)-63.64%
P/E Ratio (TTM)49.18x
EPS Growth TTM (YoY)-33.29%
Year-to-Date Return32.64%
5-Day Price Return6.61%
EPS Normalized (Annual)$0.83
ROA (5Y Avg)17.94%
Net Profit Margin (Annual)13.09%
Month-to-Date Return14.51%
Cash Flow / Share (TTM)$0.81
EBITD / Share (Annual)$0.38
EPS Growth (3Y)-1.69%
Operating Margin (Annual)5.88%
LT Debt / Equity (Annual)0.00x
P/CF (TTM)34.51x
ROI (5Y Avg)21.45%
P/E Excl Extra (TTM)49.18x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$0.83
P/TBV (Quarterly)5.63x
P/B Ratio (Annual)11.40x
Inventory Turnover (TTM)1.03x
Pretax Margin (TTM)8.73%
Book Value / Share (Annual)$6.11
Price vs S&P 500 (13W)21.76%
Net Margin Growth (5Y)-15.26%
Beta0.35x
P/FCF (Annual)34.56x
Revenue / Share (TTM)$6.34
ROE (TTM)15.34%
52-Week Low$28.66
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.75
3.75
3.75
3.92
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
CORTCorcept Therapeutics Inc. | 6.44x | 12.79% | 98.30% | -0.54% | $46.34 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Corcept Therapeutics is a pharmaceutical company developing cortisol-modulating medications for metabolic, oncologic, and neuropsychiatric disorders. The company commercializes Korlym (mifepristone) for hypercortisolism (Cushing's syndrome), with a clinical-stage pipeline including compounds targeting multiple solid tumors, ALS, and MASH.